Dana-Farber Cancer Institute | Strategic Alliance Partners

August 21, 2015

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

August 11, 2015

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

August 10, 2015

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

August 09, 2015

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

August 03, 2015

Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.

July 29, 2015

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

July 24, 2015

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

July 16, 2015

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.

July 14, 2015

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

July 06, 2015

Although BRCA1/2 mutations have been intensely studied in breast cancer for more than a decade, researchers are still seeking to determine which patient populations should be screened for abnormalities and how best to integrate that information into treatment protocols.

June 14, 2015

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

June 08, 2015

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

May 21, 2015

Combination therapy has significant potential to fill the niche of developing resistance to BTK inhibitors and rational pairings of ibrutinib with other standard treatments, including chemoimmunotherapy and CD20-targeting monoclonal antibodies (mAbs) are rapidly gaining ground.

May 20, 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

May 15, 2015

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

May 15, 2015

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

May 06, 2015

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

April 16, 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

February 18, 2015

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

February 16, 2015

To gain insight into the integration of olaparib into clinical practice, OncLive interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.